|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chau CH, Rixe O, McLeod H and Figg WD:
Validation of analytic methods for biomarkers used in drug
development. Clin Cancer Res. 14:5967–5976. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schmalfuss F and Kolominsky-Rabas PL:
Personalized medicine in screening for malignant disease: A review
of methods and applications. Biomark Insights. 8:9–14. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sexton WM, Lin Y, Kryscio RJ, Dawson DR,
Ebersole JL and Miller CS: Salivary biomarkers of periodontal
disease in response to treatment. J Clin Periodontol. 38:434–441.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lovestone S and Thambisetty M: Blood-based
biomarkers of Alzheimer's disease: Challenging but feasible.
Biomark Med. 4:65–79. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Latosinska A, Bhat A and Frantzi M:
Clinical proteomic biomarkers: Relevant issues on study design
& technical considerations in biomarker development. Clin
Transl Med. 3:72014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mahmood S, Kanwar N, Tran J, Zhang ML and
Kung SK: SHP-1 phosphatase is a critical regulator in preventing
natural killer cell self-killing. PLoS One. 7:e442442012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Best LM, van Veldhuyzen Zanten SJ,
Bezanson GS, Haldane DJ and Malatjalian DA: Serological detection
of Helicobacter pylori by a flow microsphere immunofluorescence
assay. J Clin Microbiol. 30:2311–2317. 1992.PubMed/NCBI
|
|
10
|
Deptala A and Mayer SP: Detection of
minimal residual disease. Methods Cell Biol. 64:385–420. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dunphy CH: Contribution of flow cytometric
immunophenotyping to the evaluation of tissues with suspected
lymphoma? Cytometry. 42:296–306. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Paietta E: Assessing minimal residual
disease (MRD) in leukemia: A changing definition and concept? Bone
Marrow Transplant. 29:459–465. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bagwell CB, Clark GM, Spyratos F,
Chassevent A, Bendahl PO, Stål O, Killander D, Jourdan ML, Romain
S, Hunsberger B and Baldetrop B: Optimizing flow cytometric DNA
ploidy and S-phase fraction as independent prognostic markers for
node-negative breast cancer specimens. Cytometry. 46:121–135. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
de Vries E, Noordzij JG, Kuijpers TW and
van Dongen JJ: Flow cytometric immunophenotyping in the diagnosis
and follow-up of immunodeficient children. Eur J Pediatr.
160:583–591. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kulkarni DP, Wadia PP, Pradhan TN, Pathak
AK and Chiplunkar SV: Mechanisms involved in the down-regulation of
TCR zeta chain in tumor versus peripheral blood of oral cancer
patients. Int J Cancer. 124:1605–1613. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Whiteside TL: Down-regulation of
zeta-chain expression in T cells: A biomarker of prognosis in
cancer? Cancer Immunol Immunother. 53:865–878. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ioannides CG and Whiteside TL: T cell
recognition of human tumors: Implications for molecular
immunotherapy of cancer. Clin Immunol Immunopathol. 66:91–106.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Siegel AC and Louis KS: Cell viability
analysis using trypan blue: Manual and automated methods. Methods
Mol Biol. 740:7–12. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mizoguchi H, O'Shea JJ, Longo DL, Loeffler
CM, McVicar DW and Ochoa AC: Alterations in signal transduction
molecules in T lymphocytes from tumor-bearing mice. Science.
258:1795–1798. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Travis J: Do tumor-altered T cells depress
immune responses? Science. 258:1732–1733. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Maecker HT and Trotter J: Flow cytometry
controls, instrument setup, and the determination of positivity.
Cytometry A. 69:1037–1042. 2006. View Article : Google Scholar : PubMed/NCBI
|
